FDA-cleared profile

Rapid MLS

iSchemaview Inc. · CT/CTA · FDA-cleared (510(k))

Authorized purpose: Brain midline-shift measurement on adult non-contrast CT

Clinical role
Measurement or quantification
Images and patients
CT/CTA · Brain
Key limitation
Keep in mind: Results are not intended for standalone clinical decisions and do not replace clinical assessment of NCCT cases

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Brain midline-shift measurement on adult non-contrast CT
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Brain Input: DICOM non-contrast head CT in adults
  • Who uses it?Intended users: Medical professionals using midline shift as a clinical metric
  • What does the software produce?Output: Color overlay showing expected and indicated midline at the Foramen of Monro; quantitative JSON measurement in millimeters; reports and DICOM Secondary Capture series
  • What is its most important limitation?Key limitation: Results are not intended for standalone clinical decisions and do not replace clinical assessment of NCCT cases

Clinical takeaway. Clinical role: Brain midline-shift measurement on adult non-contrast CT

Evidence takeaway. Evidence from the reviewed source record: Standalone validation used 153 NCCT cases from 13 sites (11 US, 2 outside US), ages 26-93, compared with three-expert reference. FDA-reported Rapid MAE was 0.7 mm versus expert average pairwise MAE 1.0 mm. Test cases were separate from development data.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Brain midline-shift measurement on adult non-contrast CT
  • Exact FDA submission
  • Checked 2026-09-05
Workflow role
Measurement or quantification
  • Exact FDA submission
  • Checked 2026-09-05
Required input
DICOM non-contrast head CT in adults
  • Exact FDA submission
  • Checked 2026-09-05
Output and clinician action
Color overlay showing expected and indicated midline at the Foramen of Monro; quantitative JSON measurement in millimeters; reports and DICOM Secondary Capture series
  • Exact FDA submission
  • Checked 2026-09-06
Care setting
Adult brain CT assessment, including hemorrhage, tumor and traumatic brain injury contexts
  • Exact FDA submission
  • Checked 2026-09-05
Intended users
Medical professionals using midline shift as a clinical metric
  • Exact FDA submission
  • Checked 2026-09-05
Limitations
Results are not intended for standalone clinical decisions and do not replace clinical assessment of NCCT cases
  • Exact FDA submission
  • Checked 2026-09-05
Evidence summary
Standalone validation used 153 NCCT cases from 13 sites (11 US, 2 outside US), ages 26-93, compared with three-expert reference. FDA-reported Rapid MAE was 0.7 mm versus expert average pairwise MAE 1.0 mm. Test cases were separate from development data.
  • Exact FDA submission
  • Checked 2026-09-06

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
Standalone validation used 153 NCCT cases from 13 sites (11 US, 2 outside US), ages 26-93, compared with three-expert reference. FDA-reported Rapid MAE was 0.7 mm versus expert average pairwise MAE 1.0 mm. Test cases were separate from development data.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-06
Reported sensitivity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-05

Measurement-error evaluation does not establish a diagnostic sensitivity for a binary clinical condition.

Reported specificity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-05

A diagnostic specificity was not established by the reviewed measurement study.

Midline-shift mean absolute error

0.7 mm

  • EndpointDifference from three-expert reference midline shift
  • Population153 adult NCCT cases, 13 sites, age 26-93
  • Tested versionRapid MLS in K243378; release number not stated

K243378 standalone midline-shift validation

  • DesignBlinded standalone comparison with three-expert reference, data separate from development
  • PopulationAdults age 26-93; GE, Philips, Toshiba and Siemens NCCT
  • Scopeexact submission
  • Tested versionRapid MLS in K243378
  • Samplen=153
  • Sites13
  • IndependenceIndependence not established

K243378

Automated midline-shift measurement evaluation reported in AJNR

  • DesignRetrospective multicenter expert-reference comparison
  • Population153 adult artifact-free CT cases with intracranial pathologies from 13 centers
  • Scopeproduct family
  • Tested versionRapid MLS; exact version not established in reviewed abstract
  • Samplen=153
  • Sites13
  • IndependenceIndependence not established

PMID:42481415 · doi:10.3174/ajnr.A9540

Abstract reports 0.8 mm MAE and tendency to underestimate shifts greater than 10 mm. Not substituted for FDA 0.7 mm result. Cohort may overlap regulatory data; not counted as independent replication.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: DICOM non-contrast head CT in adults

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-05 · Rapid MLS: K243378 decision and 510(k) summary

  2. Routing

    Source context, not route validation: NCCT processing module within Rapid Platform, with command-line interface and DICOM/JSON outputs

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-06 · Rapid MLS: K243378 decision and 510(k) summary

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. The exact FDA decision document was reviewed on 2026-11-14 and does not state where the subject device's software runs or how it is hosted. Confirm the deployment model, hosting, data flow, and current commercial configuration with the vendor.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 ·

  4. Returned objects

    Source context, not route validation: Color overlay showing expected and indicated midline at the Foramen of Monro; quantitative JSON measurement in millimeters; reports and DICOM Secondary Capture series

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-06 · Rapid MLS: K243378 decision and 510(k) summary

  5. Viewer/worklist/report

    Unresolved route: Color overlay showing expected and indicated midline at the Foramen of Monro; quantitative JSON measurement in millimeters; reports and DICOM Secondary Capture series

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-06 · Rapid MLS: K243378 decision and 510(k) summary

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Integration
NCCT processing module within Rapid Platform, with command-line interface and DICOM/JSON outputs
  • Exact FDA submission
  • Checked 2026-09-06
Security
RapidAI's current platform security and compliance one-pager states that its portfolio uses encryption at rest and in transit, role-based access control, monitoring/logging and listed HIPAA, GDPR, ISO 13485, ISO 27001, ISO 27701 and SOC 2 Type 1 claims.
  • Vendor-wide
  • Checked 2026-10-25

This is a current vendor-wide statement, not an independent attestation for the exact K223396 release; site-specific architecture, retention, contractual scope and current certification evidence remain unestablished.

Monitoring
RapidAI's security and compliance one-pager (Rev 8, published by iSchemaView, Inc.) states continuous infrastructure monitoring and system telemetry to detect operational anomalies in real time, plus a formal incident response and escalation framework with defined communication protocols.
  • Vendor-wide
  • Checked 2026-10-27

Vendor statement, not an attestation. No certificate or audit report was read; the one-pager names the RapidAI platform generally and does not scope these commitments to any specific product release; exact-release scope is not established.

Family midline-shift visualization

RapidAI's hemorrhagic-care page specifically describes Rapid MLS measurement and visualization

product family · checked 2026-09-05

Other modules' hemorrhage volume, triage and reimbursement claims are not attributed to MLS.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K243378
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05

NCCT only for this module; the controlled CT/CTA category does not imply CTA input.

Anatomy
Brain
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2025-05-28
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-06Last searched
20Fields reviewed
12Source classes checked
1Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

Stored PubMed candidate and live abstract reviewed; retained as family evidence with uncertain version and possible regulatory cohort overlap. Stored trial array empty. The current discovery snapshot contains 1 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor security document, vendor product page, literature index, peer reviewed publication, trial registry, recall database, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-06 - Exact FDA submission

    Exact-name price/procurement search did not yield a reviewed primary-source module quote; platform bundle costs remain unestablished.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission

    Bounded web search on 2026-10-26 (query: "Rapid CTA 360 RapidAI reimbursement CPT NTAP"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. RapidAI's reimbursement page lists NTAP for Rapid LVO (FY2021-2022 rules); it does not name this product. This records what was found, not that none exists; eligibility depends on payer, site of service and use case.

  • Deployment: Not publicly available - checked 2026-11-14 - Exact FDA submission

    The exact FDA decision document was reviewed on 2026-11-14 and does not state where the subject device's software runs or how it is hosted. Confirm the deployment model, hosting, data flow, and current commercial configuration with the vendor.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-05 - Exact FDA submission

    End-user onboarding, large-shift review guidance and local competency requirements remain unestablished.

11 sources - 3 history items

Source ledger

  1. Rapid MLS: K243378 decision and 510(k) summary

    U.S. Food and Drug Administration - Accessed 2026-09-06

    Scope: identity, clinical, evidence, implementation

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Rapid MLS model card (K243378)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. Rapid MLS: K243378 decision and 510(k) summary

    U.S. Food and Drug Administration - Accessed 2026-09-06

    Scope: identity, clinical, evidence, implementation

  8. Hemorrhagic Stroke Solutions

    RapidAI - Accessed 2026-09-05

    Scope: implementation

  9. Rapid MLS midline-shift measurement study, AJNR A9540

    AJNR / PubMed - Published 2026-07-21 - Accessed 2026-09-05

    Scope: evidenceStudies

  10. RapidAI security and compliance one-pager

    RapidAI - Accessed 2026-09-08

    Scope: vendorWideSecurity, deployment, implementationCapabilities

  11. RapidAI security and compliance one-pager (Rev 8)

    iSchemaView, Inc. (RapidAI) - Accessed 2026-10-27

    Scope: security, monitoring

Research history

  1. K243378 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K260406

Brainomix 360 Hyperdensity

Brainomix Limited

Authorized purpose: Provides volumetric hyperdensity segmentation and quantification as an aid; physicians must review original images.

Modality
CT/CTA
Anatomy
Brain
Decision
2026-06-12
FDA-cleared K251151

Rapid CTA 360

iSchemaView

Authorized purpose: Rapid CTA 360 analyzes adult head CTA DICOM images to flag suspected large- and medium-vessel occlusion in specified intracranial and vertebral segments and notify trained clinicians for workflow triage; notifications are informational and not diagnostic.

Modality
CT/CTA
Anatomy
Brain
Decision
2025-07-16
FDA-cleared K250354

Viz Subdural+, Viz SUBDURAL PLUS

Viz.ai, Inc.

Authorized purpose: Viz Subdural+ labels, visualizes, and quantifies subdural collections from single-time-point non-contrast head CT, reporting collection grayscale value, total volume, widest width, and midline shift as annotated DICOM images for physician review with original CT.

Modality
CT/CTA
Anatomy
Brain
Decision
2025-06-10
FDA-cleared K243294

Brainomix 360 e-ASPECTS

Brainomix Limited

Authorized purpose: Brainomix 360 e-ASPECTS registers adult non-contrast brain CT, segments ASPECTS regions, and provides an editable ASPECTS score with highlighted regions and voxel contribution views to assist trained clinicians evaluating suspected ischemic stroke within 24 hours of last known well.

Modality
CT/CTA
Anatomy
Brain
Decision
2025-02-14

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history